The miR-483-3p is upregulated in several tumors, including liver tumors, where it inhibits TP53-dependent apoptosis by targeting the pro-apoptotic gene BBC3/PUMA. The transcriptional regulation of the miR-483-3p could be driven by the β-catenin/USF1 complex, independently from its host gene IGF2, and we previously demonstrated that in HepG2 hepatoblastoma cells carrying wild-type TP53 the upregulation of the miR-483-3p overcomes the antitumoral effects of the tumor-suppressor miR-145-5p by a mechanism involving cellular glucose availability. Here we demonstrate that in HepG2 cells, the molecular link between glucose concentration and miR-483-3p expression entails the O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT), which stabilizes the transcriptional complex at the miR-483 promoter. HepG2 cells showed reduced miR-483-3p expression and increased susceptibility to 5-fluorouracil (5-FU)-induced apoptosis in presence of the inhibitor of glycolysis 2-deoxy-D-glucose (2-DG). However, in vivo experiments showed that HepG2 cells with higher miR-483-3p expression were selected during tumor progression regardless of 5-FU treatment. Furthermore, treatment with 2-DG alone did not significantly reduce HepG2 xenograft load in immunodeficient mice. In conclusion, we show that in HepG2 cells glucose uptake increases the expression of the oncogenic miR-483-3p through the OGT pathway. This suggests that depletion of the miR-483-3p may be a valuable therapeutic approach in liver cancer patients, but the use of inhibitors of glycolysis to achieve this purpose could accelerate the selection of resistant neoplastic cell clones.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common form of cancer worldwide and the third cause of cancer-related deaths. 1, 2 The current therapies are limited and often ineffective, thus there is a need to identify new druggable molecular targets for the development of novel therapeutics.
We have previously shown that miR-483-3p is overexpressed in HCCs that carry mutations in β-catenin pathway genes 3 and in HCCs with wild-type TP53, as compared with those with mutated TP53. 4 The miR is transcribed through the β-catenin (CTNNB1)/USF1 complex and targets the important downstream apoptotic factor of TP53, PUMA. 3, 5 This gives to the miR a role in HCC tumorigenesis, based on the induction of resistance to apoptosis. Indeed, we have previously shown that in hepatoblastoma HepG2 cells, which carry mutated CTNNB1 and wild-type TP53, constant activation of the TP53/miR-145-5p signaling selects cells with high miR-483-3p expression that are resistant to apoptosis. Depletion of miR-483-3p leads to apoptosis of these cells. We also demonstrated that miR-145-5p influences the expression of miR-483-3p in HepG2 cells with stimulatory or inhibitory effects, depending on the availability of glucose in the culture media. 4 The involvement of glucose metabolism in the regulation of miR-483-3p is supported by several studies that connect CTNNB1 and USF1 activity to cellular glucose metabolism, [6] [7] [8] and by the fact that miR-483-3p maps at the INS-IGF2 locus, which is involved in the insulin pathway. 9, 10 Here we show that in HepG2 cells the expression of miR-483-3p is affected by the extracellular concentration of glucose. In fact both glucose starvation and treatment with the glucose-mimic 2-DG reduce miR-483-3p expression. We identify as a key factor of this regulation the O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT). OGT is responsible for O-linked β-N-Acetylglucosamine (O-GlcNAc) protein modifications using the activated derivative of glucose metabolism Uridine diphosphate N-acetylglucosamine or UDP-GlcNAc as substrate. Therefore, protein O-GlcNAcylation is considered a cellular nutrient sensor and a metabolic regulator. 11, 12 On the basis of our previous study, which showed increased cell death susceptibility in HepG2 cells following depletion of the miR-483-3p after inhibition of glucose metabolism, we tested 2-DG as an adjuvant treatment, combined with 5-fluorouracil (5-FU), on a murine xenograft model with tumors induced by peritoneal injection of HepG2 cells.
RESULTS

Glucose concentration affects miR-483-3p expression in HepG2 cell line
MiR-483-3p is regulated by the transcriptional factors CTNNB1 and USF1, therefore, on the basis of our previous observations, we speculated that glucose deprivation could reduce the expression of this miRNA. To study the effect of glucose deprivation on miR-483-3p expression, we cultured HepG2 cells with either no-glucose or 10 mM glucose, and we collected cells at 10, 20, 36 and 48 h. We observed a gradual and significant reduction of miR-483-3p expression in cells cultured in no-glucose condition; on the contrary, miR-483-3p expression increased over time in the presence of glucose ( Figure 1a ).
To investigate if the CTNNB1/USF1 complex could have a direct role on the increase of miR-483-3p expression in response to glucose in HepG2 cells, we assayed the luciferase activity of a vector carrying the E-Box-responsive element to CTNNB1/USF1 complex. 3 The luciferase values showed reduced activity in no-glucose relative to low glucose condition, indicating that the glucose-dependent miR-483-3p regulation could be transcriptionally controlled by CTNNB1/USFl (Figure 1b ).
To strengthen these data, we treated HepG2 cells with the glucose antagonist 2-deoxy-D-glucose (2-DG) for 48 h. We observed a significant reduction of the levels of both the miR-483-3p and its precursor pri miR-483 in a 2-DG concentration-dependent way. The host gene IGF2 was not affected, suggesting that glucose deprivation regulated the transcription of miR-483-3p independently of IGF2 (Figure 1c ).
To establish if 2-DG treatment affected miR-483-3p expression by altering the activity of the CTNNB1/USF1 complex, we measured the luciferase activity of the vectors carrying either wild-type or mutated CTNNB1/USF1-responsive elements in HepG2 cells. Cells were grown in low or high glucose media and treated or not with 2-DG. The assay showed that, upon 2-DG treatment, the promoter was less activated in both glucose conditions and the response to 2-DG was absent or much less evident using the vector harboring the mutant sequence ( Figure 1d ). Overall, these results indicate the involvement of the CTNNB1/USF1/E-box complex in the regulation of miR-483-3p expression.
To further investigate this hypothesis, we treated HepG2 cells with 2-DG for 2 weeks and we observed a significant reduction of the levels of miR-483-3p and CTNNB1 (Figure 2a ). Next, we evaluated the activity of the CTNNB1/USF1 complex on the miR-483 promoter in HepG2 cells upon 2-DG treatment. The compound was able to reduce the interaction between the CTNNB1/USF1 complex and the probe, as demonstrated by the reduction of the specific bands 'b' (37%) and 'c' (-27%). The specificity of the complex was demonstrated by the supershift using the anti-USF1 antibody (band 'a') that showed a reduction of intensity of about 38% after treatment ( Figure 2b ). We also noted a reduction of the nuclear fraction of mutated CTNNB1 and USF1 in cells treated in the same conditions ( Figure 2c ). These findings suggest the 2-DG influences miR-483-3p expression by reducing both the amount of the CTNNB1/USF1 complex and its affinity for the E-box element upstream the miR-483 gene.
OGT activity regulates miR-483-3p expression acting at the transcriptional level OGT contributes to β-catenin stabilization 13, 14 and is related to the insulin pathway; 15 thus we investigated its role in the glucosedependent regulation of miR-483-3p. We evaluated miR-483-3p To confirm the regulation of miR-483-3p by OGT, we treated HepG2 cells with azaserine, a OGT inhibitor. As shown in Figure 3b , the compound reduced miR-483-3p and primiR-483-3p expression, suggesting an effect on its transcription.
To study if OGT modulates miR-483-3p expression by acting on the CTNNB1/USF1 complex, we conducted a chromatin immunoprecipitation analysis for USF1 occupancy at the promoter of miR-483 (6841F-7100R) in HepG2 cells transfected with either siCTRL or siOGT. The 3′ UTR of the gene UBE3A (3UTR-UBE3A) was added as control. The siOGT treatment reduced the affinity between USF1 and the miR-483 E-box sequence, suggesting that OGT is fundamental for USF1 activity and in turn the regulation of the miR-483-3p expression ( Figure 3c ). BUB1 antibody was used as negative immunoprecipitation control, sonication and transfection controls are reported in Supplementary Figure S1A.
To confirm these data, we performed electrophoretic mobility shift assay analysis of HepG2 nuclear protein extracts obtained after transfection with OGT-siRNA or azaserine treatment; the miR-483 E-box was used as probe. This showed that OGT inhibition reduces the specific binding of the USF1 complex to the miR-483 E-box (Figure 3d , left). Western blot analysis of the nuclear protein extract confirmed OGT reduction after siOGT treatment. Despite the physiologically increased expression of OGT protein after azaserine treatment, a reduction of the overall glycosylation status was observed by using the O-GlcNAc antibody (RL2), which binds O-linked N-acetylglucosamine residues (Figure 3d , right). The effects of azaserine and of OGT-siRNA on miR-483-3p and primiR-483 are reported in Supplementary Figure S1B. Based on our previously published evidence of an interplay between miR-483-3p and the TP53 pathway, 4 we measured the mRNA expression of the TP53 transcriptional target BBC3 gene upon silencing of OGT and 2-DG treatment. Decreased miR-483-3p expression was concomitant to increased BBC3 RNA levels, index of TP53 activity (Supplementary Figure S1C) .
Then, given that the OGT gene is a predicted target of the miR-483-3p by TargetScan (http://www.targetscan.org/vert_71/), we tested by western blot OGT expression in HepG2 cells transfected with either miR-483-3p mimic or anti-miR-483-3p (AMO-483-3p). Compared with the controls, no differences in OGT expression were observed (Supplementary Figure S1D ), indicating that OGT is not a target of miR-483-3p in HepG2 cells.
To verify whether CTNNB1 directly interacts with OGT in our cell model, we performed an immunoprecipitation analysis in HepG2 cells transfected with a vector carrying USF1. We observed an interaction between CTNNB1 and OGT, suggesting that OGT regulated miR-483-3p expression by affecting the stability of CTNNB1 (Supplementary Figure S2 ).
Effect of 2-DG on HepG2 cells in vitro and in vivo
Given that miR-483-3p was proven to have an oncogenic role in HCC 5 and to inhibit the pro-apoptotic pathway induced by miR-145-5p and TP53, 4 we hypothesize that 2-DG could reduce miR-483-3p expression and increase the efficacy of chemotherapeutic treatments in HCC cells.
Anti-miR-483-3p in combination with 2-DG was tested on HepG2 cells treated with different anticancer drugs, including sorafenib, doxorubicin and 5-FU. Inhibition of miR-483-3p significantly increased 5-FU-induced apoptosis in 2-DG treated cells (Supplementary Figure S3A ). Next, we treated HepG2 cells with 2-DG (10 and 20 mM) alone or in combination with 5-FU (2.5 μM) and we evaluated caspase 3/7 activity. The combination of the two compounds resulted in higher caspase activity compared with the control (Figure 4a ), which was confirmed by analysis of Supplementary Figure S3B .
To evaluate the effect of the drugs in vivo, we generated a xenograft model in which NOD scid gamma mice were intraperitoneally inoculated with HepG2. Mice were treated with intraperitoneal injection of 2-DG (250 mg/kg one injection), or 5-FU (12.5 mg/kg for 3 consecutive days), or combination of the two drugs, or phosphate-buffered saline (PBS). We alternated a week of treatment with a week of rest, for a total of three cycles (Figure 5a ). After 3 days from the last treatment, the mice were sacrificed and the xenografts were weighted. We observed reduction of tumor volume after treatment with 5-FU; however, addition of 2-DG did not improve 5-FU efficacy (Figure 5b ). To explain this phenomenon, we analyzed miR-483-3p RNA expression together with the protein levels of PUMA and CTNNB1, which are targets of the miR. Compared with HepG2 cells, in almost all xenografts miR-483-3p showed significantly increased expression, concomitant with downregulation of its targets (Figure 5c ) suggesting that the 2-DG, at the evaluated concentration and mode of administration, did not affect the expression of the miR in vivo.
DISCUSSION
In liver cancer, the expression of the miR-483-3p is related to the mutational status of TP53 and CTNNB1 genes and to impaired epigenetic mechanisms affecting the IGF2/miR-483/H19 locus. The overexpression of of the miR-483-3p directly inhibits protein expression of the pro-apoptotic factor TP53 upregulated modulator of apoptosis (PUMA). [3] [4] [5] Here we demonstrate that cellular glucose availability is involved in the modulation of miR-483-3p and identified OGT activity as a molecular link between glucose and miR-483-3p expression. OGT mediates the addition of a N-acetylglucosamine in O-glycosidic linkage (O-GlcNAcylation) to serine or threonine residues 16, 17 and influences several cellular processes, such as epigenetic control of RNA transcription, 18 insulin signaling, 15 Wnt/β-catenin signaling 13, 14 and mouse embryonic development. 19 Inhibition of OGT activity results in decreased miR-483-3p expression, concurrently with weakened affinity of the transcriptional complex CTNNB1/USF1 to the responsive sequence upstream the miR-483 gene. Although our data show that OGT influences the CTNNB1/USF1 complex acting at the responsive E-box element, we cannot exclude involvement of other molecular mechanisms. Indeed OGT is implicated in RNA transcription by O-GlcNAcylation of RNA polymerase II 20 and of several transcription factors, such as SP1 21 and MYC, 22 in addition to CTNNB1. 13, 14 The reprogramming of glucose metabolism and its epigenetics aspects are relevant to the development of new approaches to cancer treatment. [23] [24] [25] In this regard, the antitumoral effects of 2-DG are under intense study, 26, 27 and we found that 2-DG treatment inhibits miR-483-3p expression in HepG2 cells, probably by reducing the OGT substrate, and equally enhances the apoptotic rate of HepG2 cells treated with 5-FU. We decided to investigate the effects of co-treatment with 2-DG and 5-FU on Glucose availability regulates miR-483-3p by OGT activity F Pepe et al HepG2 xenografts in vivo. By analyzing the engrafted tumor masses, we found that tumor load decreased less in the group of mice co-treated with 2-DG and 5-FU compared with the group treated with 5-FU alone. This could be explained by the fact that miR-483-3p was not affected by 2-DG at the dose and modality of administration used. Instead of the predicted reduction of miR-483-3p expression, the xenografts showed induction of the miRNA after 2-DG and 5-FU co-treatment. This could be due to a cellular selection of clones with higher expression of the miRNA, an event that we previously observed also studying TP53 activation. 4 Altogether these results prove that the glucose/OGT/miR-483-3p signaling axis has an important role in the anti-apoptotic mechanisms of liver cancer and can be an important dowel to understand the oncogenic mechanisms that link metabolism to resistance to drugs and apoptosis. Therefore, miR-483-3p may be a promising target in the management of liver cancer patients, but the modality of its modulation should not include 2-DG or other drugs that cause general metabolic inhibition, an effect that could be counterproductive, as it would increase the selective pressure for the most adaptive cancer cells.
MATERIALS AND METHODS
Cell lines, drugs treatment and transfection
HepG2 cell line, from American Type Culture Collection (ATCC, Manassas, VA, USA), were cultured with Dulbecco's modified Eagle's medium, with low or high glucose concentration (1 g and 4.5 g per liter, respectively), completed with 10% fetal bovine serum European approved, L-glutamine, penicillin, streptomycin and Normocin (100 ug/ml) (InvivoGen, San Diego, CA, USA). RNA extraction, cDNA and quantitative real-time PCR (RT-qPCR) for miRNA and mRNA Purification of total RNA using Qiazol reagent (Qiagen, Hilden, Germany) was carried out following the manufacturer's instructions. To avoid genomic contamination in the quantification of pre-mRNA and pri-miRNA, RNA samples used for the analysis were previously treated with DNase (TURBO DNA-free Kit; Thermo Fisher Scientific). To analyze the mature miRNA expression normalized on RNU44, we synthesized specific miRNA complementary DNA (cDNA) from RNA samples. In all, 25 ng of total RNA were reverse transcribed using the cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and the specific stem loop RT primers designed with a modification to include the UPL #21 complementary sequence. 28, 29 The mix for the reverse transcription reaction included: 5 μl of RNA (5 ng/μl); 2 μl of 10X reverse transcription buffer; 0.2 μl of 100 mM dNTPs; 0.2 μl of RNase inhibitor (20 U/μl); 1 μl of MultiScribe reverse transcriptase (50 U/μl); 0.5 μl of specific loop primers (1 μM) (diluted in TRIS/HCl 2.5 mM pH 8.5) for miRNA and RNU44; and nuclease-free water to reach the final volume of 20 μl. The pulsed RT reaction was carried out in 0.2 ml tubes at 16°C for 30 min, followed by 60 cycles (30°C for 30 s, 42°C for 30 s, 50°C for 1 s) with the final step of 85°C for 5 min, using a thermal cycler GeneAmp PCR System 9700 (Thermo Fisher Scientific). Then qPCRs were performed. In total, 10 μl of qPCR reaction included: 3.4 μl of RNase-free water; 5 μl of Mastermix 2X (FastStart Universal Probe Mastermix, Roche, Basilea, Svizzera); 0.5 μl of specific miRNA primer forward (20 μM); 0.5 μl of universal reverse primer (20 μM); 0,1 μl of Universal Probe Library 21 (4686942001, Roche); 1 μl of cDNA diluted.
To quantify mRNAs normalized on ACTB expression, cDNA was generated using the High Capacity cDNA reverse transcription kit The reactions were carried out in 0.2 ml tubes at 25°C for 10 min, 37°C for 2 h and 85°C for 5 min, using the thermal cycler GeneAmp PCR System 9700 (Thermo Fisher Scientific). The cDNA obtained was diluted 1:2 and used for the qPCR using the kit FastStart Universal Probe Mastermix. The 10 μl of reaction included: 2.4 μl of RNase-free water, 5 μl of Mastermix 2X, 0.5 μl of specific mRNA primer forward (20 μM), 0.5 μl of specific mRNA primer reverse; 0.1 μl of specific probe (Universal probe library system, Roche) and 2 μl of cDNA diluted. Primer sequences and relative fluorescent 6-Carboxyfluorescein probes were obtained by the 'Universal Probe Library Assay Design Center' online software (https://lifescience.roche.com). When the identification of a suitable UPL probe was not possible, SYBR green technologies were used for the quantification of a specific sequence (QuantiFast SYBR Green PCR Kit; Qiagen), in this case the 10 μl of reaction included: 2.8 μl of RNase-free water, 5 μl of SYBR green Mastermix 2X (Qiagen); 0.1 μl of specific forward and reverse primer (20 μM); and 2 μl of cDNA diluted (1:2). qPCR reactions were conducted using an ABI PRISM 7900HT Sequence Detection System (Thermo Fisher Scientific) or the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). All samples were run in triplicate, and the levels of miRNA and mRNA were measured using the threshold cycle (Ct). The amount of target, normalized to an endogenous reference (RNU44 for miRNA and ACTB for mRNA), is given by 2 − ΔCt , with formula 2-(Ct sample-(mean triplicate of the Ct reference)) in base to the comparative Ct method (Applied Biosystems User Bulletin no. 2).
Primer sequences used are provided in Supplementary Table 1 .
Protein extraction, quantification and western blot
Total protein extraction were performed by using M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) freshly supplemented with protease and phosphatase inhibitors (Thermo Scientific); whereas the NePer kit (Thermo Fisher Scientific) was used for nuclear and cytoplasmic extraction following the manufacturer's instructions. Protein concentration was evaluated by spectrophotometric analysis using the Bio-Rad Protein Assay Dye Reagent (Bio-Rad) and the GeneQuant pro spectrophotometer (Biochrom Ltd., Cambrige, UK). Up to 50 μg of protein were loaded onto gel Criterion TGX Stain Free Gel, 4-20% (Bio-Rad) and run at 80 V for 2 h. Proteins were transferred in polyvinylidene difluoride membrane at 20 V overnight. Blots were blocked with non-fat dry milk 5% (Cell Signaling Technology, Danvers, MA, USA) for 1 h at room temperature and incubated 
Immunoprecipitations (chromatin immunoprecipitation)
Immunoprecipitation was executed using the kit Magna ChIP Protein A+G Magnetic Beads (Merck Millipore, Billerica, MA, USA) following the manufacturer's instructions. Cells were fixed with formaldehyde (1% 10 min at room temperature), glycine was added to stop the reaction and after 5 min, then washed with ice-cold cold PBS to remove completely the formaldehyde. Cells were collected by scraping in PBS ice cold containing 1x proteinase inhibitor, pelleted and lysed with buffer containing proteinase inhibitors. After vortex and centrifugation, the supernatant was separated and the nuclear lysis buffer added to the pellet. After centrifugation to remove the debris, the protein nuclear extract was sonicated using an IKA Labor technik U200 S Control apparatus (IKA-Works, Staufen im Breisgau, Germany, 30% amplitude, 0.3-s pulse rate or 30% cycle duty for 1 min). Part of the lysate sonicated was denatured and run for gel electrophoresis to confirm that the length of the DNA fragments was between the 200 and 1000 base pairs. The rest of the lysate was centrifuged to remove debris and used for the different immunoprecipitations. Each immunoprecipitation was conducted with 50 μl of lysate diluted in 450 μl of dilution buffer containing protease inhibitors. In all, 5 μl were removed and keep at − 80°C (input). For each experimental condition, 1 µg of USF1 antibody or controls (mouse IgG, BUB1 antibody) and 20 µl of fully resuspended protein A/G magnetics beads were added to the diluted lysate. All the reactions were incubated overnight at 4°C with rotation. The protein A/G magnetic beads were pellet with the magnetic separator and washed with specific salt solutions. Then elution buffer containing the proteinase K was added and the samples were incubated at 62°C for 2 h and 95°C for 10 min with shaking. Beads were separated with the magnetic separator and the supernatant containing the DNA associated at the protein complexes were purified by columns. In all, 2 μl of the obtained DNA were used for qPCR to quantify the miR-483-3p promoter region using the primers 6841_F and 7100_R, or the 3'UTR region of UBE3A as control. For qPCRs, every sample was analyzed in triplicate.
Caspase 3/7 activity and Annexin V flow cytometric analysis
HepG2 and Hep3B cells were seeded in a 96-well plate with opaque borders. After the transfection and/or the drug treatment, the cellular apoptosis was evaluated by the Caspase-Glo 3/7 Assay (Promega), following the manufacturer's procedure. The luminescence was evaluated by the Veritas Microplate Luminometer (Turner BioSystems, Promega). Every sample was analyzed in triplicate.
Another assay to measure apoptosis was performed by fluorescenceactivated cell sorter using Annexin V-APC conjugated detection kit (Enzo Life Sciences, Farmingdale, NY, USA). After washing in PBS, cells were stained using Annexin V antibody in specific binding buffer for 10 min in darkness, according with the manufacturer's procedure. Then cellular apoptosis was analyzed by flow cytometer (FACSCalibur, BD).
Mice treatment and management
Animal studies were approved by institutional and government ethical committees (823/2015-PR). Sixteen NOD scid gamma (Charles River Breeding Laboratories, Wilmington, MA, USA) male mice were used (four for each group). No mice randomization was performed and no blinding procedures were performed. All mice were housed in the Aging Research Center (CeSI-MeT, Chieti, Italy) animal facility. They were maintained on a 12-h light/dark cycle with ad libitum access to water and normal chow. The suffering of the mice was evaluated using the 'mouse grimace scale' 30 by the responsible of the stabulary and no suffering status was registered during the management and the treatment. The cages, the water, the chow and every items or substance that was in contact with the mice were sterile. The mice of 6 weeks were inoculated with 10 7 HepG2 cells by intraperitoneal injection using a 26-gauge syringe and divided in four groups of treatment: PBS, 2-DG, 5-FU and 2-DG+5-FU.
Then, three cycles of treatment were executed at 11, 25 and 39 day from the HepG2 injection. The administration of 2-DG (250 mg/kg) was once at treatment, whereas for 5-FU was decided to execute three separate administration during the week of treatment (12.5 mg/kg each). Each drug was dissolved in sterile PBS, and administered by intraperitoneal injection at a final volume of 200 μl for mouse. We used the no toxic dose of 2-DG 31 alone or in combination with 5-FU to treat mice. At 45 days from the injection of the cells, mice were sacrificed by CO 2 chamber. Tumor masses were photographed, weighted and putted in liquid nitrogen until RNA and protein extraction.
Statistical analysis
All the in vitro experiments were replicated either twice or in similar conditions or in different cellular models unless not specified in the legends. The variation within each group has been evaluated as s.d. and for the in vivo results, the Levene's test was not significant to indicate the homoscedasticity of the data. Significance was determined with the two-tailed Student's t-test. A P-value threshold o0.05 was considered significant (marked as *), P valueo0.01, o 0.001 and o0.0001 are marked as **, *** and ****, respectively. In graphs, values were presented as the mean ± s.d.
